Department of Clinical Chemistry, University of Ghent, Ghent, Belgium.
Front Biosci (Landmark Ed). 2011 Jan 1;16(4):1488-504. doi: 10.2741/3800.
Stem cell transplant recipients and acquired or inherited immune-deficiency patients could benefit from the infusion of B, T and/or NK cells. These lymphoid cells can be generated in vitro from bone marrow derived CD34+CD45+ hematopoietic stem cells (HSC). The number of cells that can be obtained in this way is limited especially in the adult. An alternative source may therefore constitute human pluripotent stem cells (PSC) such as embryonic (hESC) or induced pluripotent stem cells (hiPSC). Here, we focus on present knowledge on the generation of lymphoid cells from hESC. The two main obstacles for the generation of clinically relevant immune cells are the failure to generate from hESC long-term repopulating HSC which could be kept in culture for prolonged time; and insufficient knowledge of the selection process which generates mature T cells from CD4 CD8 double positive (DP) precursors in vitro.
造血干细胞移植受者和获得性或遗传性免疫缺陷患者可受益于 B、T 和/或 NK 细胞的输注。这些淋巴样细胞可以从骨髓来源的 CD34+CD45+造血干细胞(HSC)体外生成。通过这种方式获得的细胞数量是有限的,尤其是在成年人中。因此,一种替代来源可能是人类多能干细胞(PSC),如胚胎(hESC)或诱导多能干细胞(hiPSC)。在这里,我们重点介绍从 hESC 生成淋巴样细胞的现有知识。生成临床上相关免疫细胞的两个主要障碍是未能从 hESC 中生成可在培养中长期保存的长期重编程 HSC;以及对体外从 CD4 CD8 双阳性(DP)前体中生成成熟 T 细胞的选择过程了解不足。